

Hematologic Oncology™

U P D A T E

An Audio Review Journal for Nurses

*Management of Non-Hodgkin's Lymphomas
and Multiple Myeloma*

FACULTY INTERVIEWS

John P Leonard, MD

Rafael Fonseca, MD

Kena C Miller, MSN, FNP

Mollie Moran, MSN, CNP, AOCNP

EDITOR

Neil Love, MD



Hematologic Oncology Update for Nurses

A Continuing Nursing Education Audio Series

OVERVIEW OF ACTIVITY

More than 45 pharmaceutical agents with more than 55 distinct FDA-approved indications are currently available for the management of hematologic cancer. Although this extensive list of available treatment options is reassuring to patients and oncology healthcare professionals, it poses a challenge to clinicians who must maintain up-to-date knowledge of appropriate clinical management strategies and their efficacies and toxicities. To bridge the gap between research and patient care, this issue of *Hematologic Oncology Update for Nurses* features one-on-one discussions with leading hematologic oncology investigators and nurse practitioners. By providing information on the latest research developments in the context of expert perspectives, this activity assists oncology nurses, clinical nurse specialists and nurse practitioners with the formulation of state-of-the-art clinical management strategies to facilitate optimal patient care.

PURPOSE STATEMENT

To present the most current research developments in hematologic oncology and to provide the perspectives of investigators and nurse practitioners on the diagnosis and treatment of hematologic cancer.

EDUCATIONAL OBJECTIVES FOR THIS ISSUE OF HEMATOLOGIC ONCOLOGY UPDATE FOR NURSES

- Explore new supportive and therapeutic strategies to enhance the care of patients with non-Hodgkin's lymphoma and multiple myeloma.
- Develop a plan of care to address side effects and quality of life for patients with hematologic cancer.

ACCREDITATION STATEMENTS

This educational activity for 2.6 contact hours is provided by Research To Practice during the period of November 2010 through November 2011. Research To Practice is an approved provider of continuing nursing education by the NJSNA, an accredited approver, by the American Nurses Credentialing Center's Commission on Accreditation.

HOW TO USE THIS CNE ACTIVITY

This is an audio CNE program. This book contains CNE information, including learning objectives, faculty disclosures, a Post-test and an Educational Assessment and Credit Form. The corresponding website ResearchToPractice.com/HOUN110 also includes links to relevant abstracts and full-text articles.

The Post-test and Educational Assessment and Credit Form may be completed in this book and either mailed to Research To Practice, One Biscayne Tower, 2 South Biscayne Blvd, Suite 3600, Miami, FL 33131 or faxed to (800) 447-4310. They may also be completed online. A statement of credit will be issued only upon receipt of a completed Post-test with a score of 70 percent or better and a completed Educational Assessment and Credit Form. Your statement of credit will be mailed to you within three weeks or may be printed online.

This program is supported by educational grants from Celgene Corporation and Genentech BioOncology/ Biogen Idec.

There is no implied or real endorsement of any product by Research To Practice or the American Nurses Credentialing Center.

www.ResearchToPractice.com

Your online resource for integrated oncology education

The new www.ResearchToPractice.com remains a comprehensive online resource offering numerous interactive capabilities but now offers extended search functionality and easier access to:

- Download audio and print programs
- Sign up for audio Podcasts
- Subscribe to RTP programs
- Search specific topics of interest by specialty and tumor type
- Register for upcoming live CME/CNE events
- Watch video proceedings



VISIT TODAY!

FACULTY AFFILIATIONS

John P Leonard, MD

Richard T Silver Distinguished Professor of Hematology and Medical Oncology; Professor of Medicine, Weill Cornell Medical College Associate Director for Clinical Research Weill Cornell Cancer Center; Clinical Director Center for Lymphoma and Myeloma; Attending Physician, NewYork-Presbyterian Hospital New York, New York

Rafael Fonseca, MD

Consultant, Professor of Medicine Mayo Clinic Arizona Deputy Director, Mayo Clinic Cancer Center Scottsdale, Arizona

Kena C Miller, MSN, FNP

Nurse Practitioner Lymphoma/Myeloma Division Roswell Park Cancer Institute Buffalo, New York

Mollie Moran, MSN, CNP, AOCNP

The James Cancer Hospital at The Ohio State University Columbus, Ohio

EDITOR

Neil Love, MD

Research To Practice Miami, Florida

CONTENT VALIDATION AND DISCLOSURES

Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CNE activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — **Ms Moran** had no real or apparent conflicts of interest to disclose. The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process: **Dr Leonard** — Consulting Agreements: Biogen Idec, Biotest Pharmaceuticals Corporation, Calistoga Pharmaceuticals Inc, Celgene Corporation, Cephalon Inc, CT International, Eisai Inc, EMD Serono Inc, Genentech BioOncology, GlaxoSmithKline, Gloucester Pharmaceuticals, Immunomedics Inc, Intellikine, Johnson & Johnson Pharmaceuticals, Millennium Pharmaceuticals Inc, Novartis Pharmaceuticals Corporation, Pfizer Inc, Sanofi-Aventis, Wyeth. **Dr Fonseca** — Consulting Agreements: Amgen Inc, Bristol-Myers Squibb Company, Celgene Corporation, Genzyme Corporation, Medtronic Inc, Otsuka Pharmaceutical Co Ltd; Paid Research: Celgene Corporation, Onyx Pharmaceuticals Inc. **Ms Miller** — Advisory Committee and Speakers Bureau: Celgene Corporation, Millennium Pharmaceuticals Inc.

EDITOR — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME/CNE activities from the following commercial interests: Abraxis BioScience Inc, a wholly owned subsidiary of Celgene Corporation, Allos Therapeutics, Amgen Inc, AstraZeneca Pharmaceuticals LP, Aureon Laboratories Inc, Bayer HealthCare Pharmaceuticals/Onyx Pharmaceuticals Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Cephalon Inc, Dendreon Corporation, Eisai Inc, EMD Serono Inc, Genentech BioOncology, Genomic Health Inc, Lilly USA LLC, Millennium Pharmaceuticals Inc, Myriad Genetics Inc, Novartis Pharmaceuticals Corporation, OSI Oncology, Sanofi-Aventis and Spectrum Pharmaceuticals Inc.

RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff, planners, managers and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

If you would like to discontinue your complimentary subscription to *Hematologic Oncology Update* for Nurses, please email us at Info@ResearchToPractice.com, call us at (800) 648-8654 or fax us at (305) 377-9998. Please include your full name and address, and we will remove you from the mailing list.

QUESTIONS (PLEASE CIRCLE ANSWER):

- In the Phase III trial comparing bendamustine/rituximab (BR) to R-CHOP in the up-front treatment of follicular lymphoma (FL), indolent lymphomas and mantle-cell lymphoma, which of the following was improved with BR?**
 - Progression-free survival
 - Complete response rate
 - Both a and b
- Which of the following has been shown in the PRIMA trial with maintenance rituximab for FL?**
 - Improvement in progression-free survival
 - Improvement in overall survival
 - Both a and b
 - None of the above
- Patients receiving long-term maintenance rituximab for FL may be prone to increased incidence of sinus and respiratory infections.**
 - True
 - False
- Which of the following classes of agents are used for the treatment of multiple myeloma (MM)?**
 - Alkylating agents
 - Corticosteroids
 - IMiDs®
 - Proteasome inhibitors
 - All of the above
- Patients receiving lenalidomide for MM generally should receive prophylactic reduced-dose aspirin (81 mg).**
 - True
 - False
- Studies evaluating twice-weekly administration of bortezomib versus once-weekly administration have reported significant reductions in the incidence of treatment-related peripheral neuropathy with weekly bortezomib.**
 - True
 - False
- The VISTA trial reported that the addition of bortezomib to standard melphalan/prednisone therapy did not provide a benefit for patients with MM.**
 - True
 - False
- Osteonecrosis of the jaw is a potential complication secondary to _____.**
 - Bisphosphonate therapy
 - IMiDs
 - Proteasome inhibitors
- Bortezomib is a(n) _____.**
 - Alkylating agent
 - Antimetabolite
 - IMiD
 - Proteasome inhibitor
 - None of the above
- A clinical trial currently under way is evaluating the potential role of combining _____ for patients with rituximab-refractory FL.**
 - Bendamustine and rituximab
 - Lenalidomide and rituximab
 - Bortezomib and rituximab

EDUCATIONAL ASSESSMENT AND CREDIT FORM

Hematologic Oncology Update for Nurses — Issue 1, 2010

Research To Practice is committed to providing valuable continuing education for oncology clinicians, and your input is critical to helping us achieve this important goal. Please take the time to assess the activity you just completed, with the assurance that your answers and suggestions are strictly confidential.

PART ONE — Please tell us about your experience with this educational activity

How would you characterize your level of knowledge on the following topics?

4 = Excellent 3 = Good 2 = Adequate 1 = Suboptimal

	BEFORE	AFTER
Tolerability and efficacy of BR versus R-CHOP as first-line treatment for low-grade lymphomas	4 3 2 1	4 3 2 1
Management of lenalidomide-associated tumor flare in CLL	4 3 2 1	4 3 2 1
Risk of thrombosis and anticoagulation therapy use with IMiDs	4 3 2 1	4 3 2 1
Use of maintenance rituximab after rituximab-containing induction chemotherapy in FL	4 3 2 1	4 3 2 1
Characteristics of bortezomib-induced peripheral neuropathy	4 3 2 1	4 3 2 1

Has the activity unfairly influenced you toward a particular product or service?

Yes No

If yes, please describe what was presented:

.....

.....

.....

Will this activity help you improve patient care?

Yes No Not applicable

If yes, how will it help you improve patient care?.....

.....

.....

.....

Did the activity meet your educational needs and expectations?

Yes No

If no, please explain:

.....

.....

.....

Please respond to the following learning objectives (LOs) by circling the appropriate selection:

4 = Yes 3 = Will consider 2 = No 1 = Already doing N/M = LO not met N/A = Not applicable

As a result of this activity, I will be able to:

- Explore new supportive and therapeutic strategies to enhance the care of patients with non-Hodgkin's lymphoma and multiple myeloma..... 4 3 2 1 N/M N/A
- Develop a plan of care to address side effects and quality of life for patients with hematologic cancer. 4 3 2 1 N/M N/A

EDUCATIONAL ASSESSMENT AND CREDIT FORM (continued)

What other practice changes will you make or consider making as a result of this activity?

.....

What additional information or training do you need on the activity topics or other oncology-related topics?

.....

Additional comments about this activity:

.....

As part of our ongoing, continuous quality-improvement effort, we conduct postactivity follow-up surveys to assess the impact of our educational interventions on professional practice. Please indicate your willingness to participate in such a survey.

- Yes, I am willing to participate in a follow-up survey.
- No, I am not willing to participate in a follow-up survey.

PART TWO — Please tell us about the faculty and editor for this educational activity

	4 = Excellent	3 = Good	2 = Adequate	1 = Suboptimal				
Faculty	Knowledge of subject matter				Effectiveness as an educator			
John P Leonard, MD	4	3	2	1	4	3	2	1
Rafael Fonseca, MD	4	3	2	1	4	3	2	1
Kena C Miller, MSN, FNP	4	3	2	1	4	3	2	1
Mollie Moran, MSN, CNP, AOCNP	4	3	2	1	4	3	2	1
Editor	Knowledge of subject matter				Effectiveness as an educator			
Neil Love, MD	4	3	2	1	4	3	2	1

Please recommend additional faculty for future activities:

.....

Other comments about the faculty and editor for this activity:

.....

REQUEST FOR CREDIT — Please print clearly

Name: Specialty:

Credentials:

- MD
- DO
- PharmD
- NP
- CNS
- RN
- PA
- Other.....

Street Address:..... Box/Suite:

City, State, Zip:

Telephone:..... Fax:.....

Email:

Signature:..... Date:.....

HOUN110

To obtain a certificate of completion and receive credit for this activity, please complete the Post-test, fill out the Educational Assessment and Credit Form and fax both to (800) 447-4310, or mail both to Research To Practice, One Biscayne Tower, 2 South Biscayne Boulevard, Suite 3600, Miami, FL 33131. You may also complete the Post-test and Educational Assessment online at www.ResearchToPractice.com/HOUN110.

Hematologic Oncology™

U P D A T E

Editor	Neil Love, MD
Managing Editor and CME Director	Kathryn Ault Ziel, PhD
Scientific Director	Richard Kaderman, PhD
Executive Scientific Director	Aviva Asnis-Alibozek, PA-C, MPAS
Editorial	Clayton Campbell Gloria Kelly, PhD Akhil Kumar, MD Jean Pak Douglas Paley Margaret Peng
Director, Creative and Copy Editing	Aura Herrmann
Creative Manager	Fernando Rendina
Graphic Designers	Jessica Benitez Jason Cunnius Tamara Dabney Silvana Izquierdo Deepti Nath
Copy Editing Manager	Kirsten Miller
Copy Editors	Dave Amber Margo Harris David Hill Rosemary Hulce Pat Morrissey/Havlin Alexis Oneca Carol Peschke
Production Manager	Tracy Potter
Audio Production	Frank Cesarano
Web Master	John Ribeiro
Multimedia Project Manager	Marie Philemon
Faculty Relations Manager	Melissa Vives
Continuing Education Administrator for Nursing	Julia W Aucoin, DNS, RN-BC, CNE
Contact Information	Neil Love, MD Research To Practice One Biscayne Tower 2 South Biscayne Boulevard, Suite 3600 Miami, FL 33131 Fax: (305) 377-9998 Email: DrNeilLove@ResearchToPractice.com Email: CE@ResearchToPractice.com
For CME/CNE Information	

Copyright © 2010 Research To Practice. All rights reserved.

The compact discs, Internet content and accompanying printed material are protected by copyright. No part of this program may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording or utilizing any information storage and retrieval system, without written permission from the copyright owner.

The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

Participants have an implied responsibility to use the

newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management.

Any procedures, medications or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications or dangers in use, review of any applicable manufacturer's product information and comparison with recommendations of other authorities.

Hematologic Oncology™

U P D A T E

Copyright © 2010 Research To Practice.
This program is supported by educational grants from
Celgene Corporation and Genentech BioOncology/Biogen Idec.

Research To Practice®

Sponsored by Research To Practice.

Last review date: November 2010
Release date: November 2010
Expiration date: November 2011
Contact hours: 2.6